Palisade Bio_Logos(4.22)VSM.png
Palisade Bio to Present at Digestive Disease Week (DDW) 2024
15 févr. 2024 08h35 HE | Palisade Bio, Inc.
Carlsbad, CA, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for serious...
Palisade Bio_Logos(4.22)VSM.png
Palisade Bio Provides Corporate Update and Reiterates Guidance
13 févr. 2024 08h35 HE | Palisade Bio, Inc.
– Company announces strategic streamlining of Board to align with the current state of clinical development and corporate vision – Advancement of PALI-2108 for the treatment of moderate-to-severe...
Palisade Bio_Logos(4.22)VSM.png
Correction Notice of Palisade Bio’s Press Release Announcing the Appointment of Clinical Advisory Board Members
08 févr. 2024 14h40 HE | Palisade Bio, Inc.
Carlsbad, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc.  (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for...
Palisade Bio_Logos(4.22)VSM.png
Palisade Bio Announces Receipt of Second Milestone Payment from the US Crohn’s and Colitis Foundation for Development of PALI-2108
28 déc. 2023 08h00 HE | Palisade Bio, Inc.
- Company’s co-development partner, Giiant Pharma, Inc. (“Giiant”), receives funding as part of previously announced grant from the US Crohn’s and Colitis Foundation - Lead program, PALI-2108 for...